DermaSensor
This article appears to incorporate text from a large language model, which is prohibited in Wikipedia articles. (November 2026) |
| DermaSensor Inc. | |
|---|---|
| Type | Private |
| Industry | Medical devices |
| Founded | 2009 |
| Founders | Dr. Maurice Ferré, Chris Dewey, Cody Simmons |
Area served |
|
| Key people |
|
| Products | DermaSensor skin cancer assessment device |
| Website | dermasensor |
DermaSensor Inc. is a medical device company based in Miami, Florida.[1][2] Founded in 2009, the company developed DermaSensor, an AI-powered handheld device that uses elastic scattering spectroscopy to assess skin lesions for the risk of skin cancer.[3][4] In January 2024, the U.S. Food and Drug Administration (FDA) authorized the device as a Class II device through the De Novo pathway, making it the first AI-enabled medical device for skin cancer assessment in primary care to receive FDA authorization.[5][6] The device assesses lesions suggestive of melanoma, basal cell carcinoma and squamous cell carcinoma and indicates whether a lesion should be investigated further or monitored.[7]
History
[edit]DermaSensor was founded in 2009 by Maurice Ferré and Chris Dewey. Cody Simmons joined as chief executive officer in 2016 and is also credited as a co-founder.[8][9]
The device is based on elastic scattering spectroscopy (ESS), an optical technique developed by Boston University biomedical engineer Irving Bigio. DermaSensor licensed related patents from Bigio and Boston University.[10] Development began around 2011–2012.[1] An early version weighed about 30 lb (14 kg) and was later miniaturized into a handheld device. In 2016, the company held its first pre-submission meeting with the FDA, based on data from an earlier version of the device.[3]
Enrollment in the DERM-SUCCESS pivotal study began in 2020,[11] the same year the company raised $11.5 million in Series A financing.[12] In 2021, the device received FDA Breakthrough Device designation,[13] and in 2022 the company raised a further $10 million.[1]
On January 12, 2024, the FDA granted marketing authorization for DermaSensor through the De Novo pathway.[14][6] The agency also required additional post-market validation in patients representative of the U.S. population.[7][15] By then, the device had cost approximately $25 million to develop,[16][17] and the company had raised about $27 million in venture funding.[1] Commercial sales in the United States began in mid-2024.[2]
In October 2025, DermaSensor raised $16 million in a Series B round, bringing its total funding to $43 million.[2] The same month, it initiated a recall involving certain units of the device after identifying a potential specification issue that could result in incorrect results or delayed referrals. The FDA classified the action as a Class II recall; nine of 343 distributed units were identified as affected.[18]
In June 2026, DermaSensor received a Class IIb CE Mark under the European Union Medical Device Regulation, allowing the device to be marketed in the European Economic Area.[19] In September 2026, the company raised a further $5 million and reported that the device was being used by hundreds of healthcare provider organizations and had been used to scan more than 45,000 suspicious lesions.[20][8]
The device has received several industry awards, including an Edison Award and a MedTech Breakthrough Award in 2023,[21][22] the Health & Biotech category of the SXSW Innovation Awards in 2024,[23] and inclusion in TIME magazine's Best Inventions of 2024 list[24] and Inc. magazine's Best in Innovation list in 2025.[25] In 2026, it was also recognized by the TiE50 and Pinnacle Awards.[26][27]
Device
[edit]The DermaSensor device is a handheld instrument whose fiber-optic tip is placed on a lesion and emits short pulses of light across a range of wavelengths.[11] Five recordings are taken at different points on the lesion within seconds.[28] Because malignant and benign tissues differ in their cellular and subcellular structure, they scatter light differently,[29][30] and the device analyzes light reflected from structures beneath the skin surface rather than relying on the visual appearance of the lesion.[31]
The spectral data are analyzed using a machine-learning algorithm trained and validated on scans of benign and malignant lesions collected in clinical studies.[32][33] The device reports one of two outputs, "Monitor" or "Investigate Further"; when the latter is displayed, it also provides a similarity score from 1 to 10.[34][6]
DermaSensor is intended as an adjunct to clinical decision-making rather than as a standalone diagnostic tool.[35][36][6] Its FDA authorization limits use to physicians who are not dermatologists, for evaluating lesions suggestive of melanoma, basal cell carcinoma or squamous cell carcinoma in patients aged 40 or older.[37][6]
Clinical evidence
[edit]The DERM-SUCCESS pivotal trial enrolled more than 1,000 patients at 22 primary care sites in the United States and Australia.[38][11] Across 1,579 lesions, the device had an overall sensitivity of 95.5% and specificity of 20.7%; among patients aged 40 or older, sensitivity was 96.3%.[11] Participating primary care physicians had a sensitivity of 83.0% in identifying malignant lesions.[14] The device's sensitivity was broadly similar across skin phototypes; however, 97.1% of participants were White and about 13% had Fitzpatrick skin types V or VI.[5][11]
In a 2023 clinical utility study, use of the device increased the sensitivity of primary care physicians' referral decisions from 81% to 94%, with no statistically significant change in specificity.[35] In a 2025 multi-reader study conducted as part of DERM-SUCCESS, the proportion of missed cancers fell from 18.0% to 8.6%, while referral specificity decreased from 44.2% to 32.4%.[33]
In a study of lesions that patients themselves found concerning, the device had a sensitivity of 90.0% and specificity of 60.7%; unaided primary care clinicians had lower sensitivity but higher specificity.[39] In the DERM-ASSESS III study of lesions biopsied by dermatologists in a high-risk population, the device detected 95.5% of melanomas, with a specificity of 32.5%.[30][40]
The device's relatively low specificity may lead to false-positive results and additional referrals of benign lesions; its performance has been compared with that of Nevisense, another FDA-approved device with similarly high sensitivity and low specificity. Because DERM-SUCCESS evaluated lesions that primary care physicians had already selected for biopsy, it did not assess the device as a general screening tool.[41]
A 2026 horizon-scanning assessment by Singapore's Agency for Care Effectiveness found that DermaSensor showed high sensitivity but low-to-moderate specificity across the available evidence, while its overall effects on diagnostic accuracy, management decisions and healthcare resource use remained uncertain. The assessment also noted limited representation of Asian patients in the key studies, that the key studies had been funded by DermaSensor, and that no cost-effectiveness studies had been identified.[36]
References
[edit]- 1 2 3 4 Dahlberg, Nancy (January 17, 2024). "DermaSensor gains FDA clearance for its AI-powered skin cancer detection device". Refresh Miami.
- 1 2 3 Dahlberg, Nancy (October 2, 2025). "DermaSensor raises $16M to get its AI-powered skin cancer detection device to more primary care doctors". Refresh Miami.
- 1 2 Taylor, Phil (January 18, 2024). "FDA clears AI skin cancer detection device from DermaSensor". pharmaphorum.
- ↑ "US FDA clears DermaSensor's skin cancer detection device". Medical Device Network. January 18, 2024.
- 1 2 Venkatesh, Kaushik P.; Kadakia, Kushal T.; Gilbert, Stephen (2024-06-15). "Learnings from the first AI-enabled skin cancer device for primary care authorized by FDA". npj Digital Medicine. 7 (1). Nature Publishing Group: 156. doi:10.1038/s41746-024-01161-1. ISSN 2398-6352. PMC 11180084. PMID 38879640.
- 1 2 3 4 5 U.S. Food and Drug Administration. "Device Classification Under Section 513(f)(2) (De Novo): DermaSensor, DEN230008". FDA.
- 1 2 Farrell, James (January 17, 2024). "FDA Clears AI-Powered Handheld Device That Can Detect Skin Cancer". Forbes.
- 1 2 "DermaSensor raises $5M, opens funding to public". South Florida Business Journal.
- ↑ "Spotting Trouble". Florida Trend.
- ↑ Thurston, Andrew (February 8, 2024). "Innocent Mole or Skin Cancer? FDA Clears Device with BU-Developed Technology That Makes Detection Easier". Boston University, The Brink.
- 1 2 3 4 5 Merry, Stephen P.; Croghan, Ivana T.; Dukes, Kimberly A.; McCormick, Brian C.; Considine, Gerard T.; Duvall, Michelle J.; Thompson, Curtis T.; Leffell, David J. (2025-10-01). "Primary Care Physician Use of Elastic Scattering Spectroscopy on Skin Lesions Suggestive of Skin Cancer". Journal of Primary Care & Community Health. 16 21501319251344423. SAGE Publications Inc. doi:10.1177/21501319251344423. ISSN 2150-1319. PMC 12144386. PMID 40470593.
- ↑ Dahlberg, Nancy (June 4, 2020). "DermaSensor raises $11.5 million in Series A round". Refresh Miami.
- ↑ "FDA genehmigt erstes KI-gestütztes Diagnosetool für Hautkrebs". AIM at Melanoma Foundation. January 18, 2024.
- 1 2 Taylor, Nick Paul (January 18, 2024). "Dermasensor wins FDA clearance for AI-enabled skin cancer detection device". MedTech Dive.
- ↑ "FDA Clears AI-Powered Device for Noninvasive Skin Cancer Testing". MDedge Dermatology.
- ↑ Barsukova, Olena (January 26, 2024). "У США регулятор схвалив пристрій на основі ШІ для діагностики раку шкіри". Українська правда. Життя.
- ↑ "¡Usan Inteligencia Artificial para detectar el cáncer de piel!". ExpoMedHub.
- ↑ U.S. Food and Drug Administration. "Class 2 Device Recall DermaSensor". FDA.
Recall no. Z-0583-2026
- ↑ "DermaSensor secures CE Mark, expands AI-powered skin cancer detection technology into Europe". Med-Tech World.
- ↑ "DermaSensor Raises $5 Million and Announces Four New U.S. Partnerships". Boston Life Sciences Times. 9 September 2026.
- ↑ "29 cutting-edge medtech innovations recognized with Edison Awards featuring Endiatx and DermaSensor". MedTech Innovator. February 9, 2023.
- ↑ "2023 MedTech Breakthrough Award Winners". MedTech Breakthrough.
- ↑ Seijo, Luis (12 March 2024). "2024 SXSW Innovation Awards Winners Announced". SXSW. Archived from the original on 12 March 2024.
- ↑ "The Best Inventions 2024 – Simplifying Skin Cancer Detection". TIME. 30 October 2024.
- ↑ Dahlberg, Nancy (2026). "DermaSensor is expanding internationally with its skin-cancer detection device". Refresh Miami.
- ↑ "TiE50 Awards 2026 Highlights Rising Startups Across AI, Health, And Deep Tech". indica News. April 2026.
- ↑ "Winners – Technology 2026". Pinnacle Awards.
- ↑ Sharma, Sejal (January 24, 2024). "US FDA approves world's first AI-powered skin cancer detecting device". Interesting Engineering.
- ↑ "Вчені створили пристрій на основі ШІ для діагностики трьох найпоширеніших видів раку". Espreso TV.
- 1 2 Hartman, Rebecca I.; Trepanowski, Nicole; Chang, Michael S.; Tepedino, Kelly; Gianacas, Christopher; McNiff, Jennifer M.; Fung, Maxwell; Braghiroli, Naiara Fraga; Grant-Kels, Jane M. (2024). "Multicenter prospective blinded melanoma detection study with a handheld elastic scattering spectroscopy device". JAAD International. 15: 24–31. doi:10.1016/j.jdin.2023.10.011. ISSN 2666-3287. PMC 10869922. PMID 38371666.
- ↑ "¿Cómo es el dispositivo de IA que la FDA aprobó para detectar el cáncer de piel?". Su Médico. January 19, 2024.
- ↑ "How an AI device the size of a phone detects skin cancer". NBC4 Washington. 21 February 2024.
- 1 2 Ferris, Laura K.; Jaklitsch, Erik; Seiverling, Elizabeth V.; Agresta, Thomas; Cyr, Peggy; Caines, Laurie; Wang, Na; Siegel, Daniel M. (2025-10-01). "DERM-SUCCESS FDA Pivotal Study: A Multi-Reader Multi-Case Evaluation of Primary Care Physicians' Skin Cancer Detection Using AI-Enabled Elastic Scattering Spectroscopy". Journal of Primary Care & Community Health. 16 21501319251342106. SAGE Publications Inc. doi:10.1177/21501319251342106. ISSN 2150-1319. PMC 12126654. PMID 40448353.
- ↑ "Câncer de pele: FDA aprova 1º dispositivo portátil que ajuda a detectar o tumor". Instituto Oncoguia.
- 1 2 Jaklitsch, Erik; Thames, Todd; de Campos Silva, Thomaz; Coll, Patrick; Oliviero, Margaret; Ferris, Laura Korb (2023). "Clinical Utility of an AI-powered, Handheld Elastic Scattering Spectroscopy Device on the Diagnosis and Management of Skin Cancer by Primary Care Physicians". Journal of Primary Care & Community Health. 14 21501319231205979. doi:10.1177/21501319231205979. PMC 10631325. PMID 37933569.
- 1 2 Agency for Care Effectiveness (Singapore) (April 30, 2026). "DermaSensor as an adjunctive diagnostic tool for lesions suspicious for skin cancer".
- ↑ "Cancro della pelle, Fda approva device per valutazione precoce con l'intelligenza artificiale". PharmaStar. January 18, 2024. Archived from the original on October 9, 2025.
- ↑ Dahlberg, Nancy (2025). "DermaSensor's device, now in the market, detects 96% of skin cancers and increases skin cancer referrals, FDA studies find". Refresh Miami.
- ↑ Tepedino, Miguel; Baltazar, David; Hanna, Karim; Bridges, Alina; Billot, Laurent; Zeitouni, Nathalie C. (2024). "Elastic Scattering Spectroscopy on Patient-Selected Lesions Concerning for Skin Cancer". Journal of the American Board of Family Medicine. 37 (3): 427–435. doi:10.3122/jabfm.2023.230256R2. PMID 39142857.
- ↑ Son, Hyeong-min (January 24, 2024). "'피부암 AI 진단기' 미국서 상용화…국내도 임상 막바지". Dailypharm.
- ↑ "The State of AI in Dermatology". Practical Dermatology. January–February 2025.